Kodiak Sciences Inc. announced the appointment of Jason S. Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer. Dr. Ehrlich joins other recent key additions to Kodiak's leadership team: Almas Qudrat, M.Sc., Vice President, Quality Operations, and J. Pablo Velazquez-Martin, M.D., Vice President, Clinical Research and Translational Medicine. Prior to joining Kodiak, Dr. Ehrlich served as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group. In roles of increasing responsibility at Genentech/Roche from 2008-2018, Dr. Ehrlich was lead clinician for Lucentis in diabetic eye disease resulting in the first-ever FDA approval of an intraocular drug for diabetic macular edema. He then led efforts to expand Lucentis labeling into all forms of diabetic retinopathy, into choroidal neovascularization due to pathologic myopia, and the FDA approval of the Lucentis pre-filled syringe. Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1,800 patients, over 275 sites, and more than 20 countries. He guided the successful transition to global Phase III development of faricimab, a novel bispecific antibody for retinal vascular disease. Ms. Qudrat has more than 25 years of experience in managing and directing quality activities for biotechnology and pharmaceutical companies. Her experience spans all stages of drug development from first in human to commercial products. She has been responsible for small molecules, biologics, tablets, capsules, pre-filled syringes, vials, and combination products via intravenous, subcutaneous, intravitreal, inhalable, as well as transdermal routes of administration. Ms. Qudrat led the pre-approval inspections that brought Botox (Allergan), Myoblock (Elan), and Exubera (Nektar-Pfizer) to the market and supported, prepared, and contributed to multiple pre-approval activities for other products including the Lucentis pre-filled syringe (Roche/Genentech). Before joining Kodiak, Ms. Qudrat held positions of increasing responsibility at Abbott, Baxter, Elan, Allergan, Nektar, Avidia, Amgen, Jazz Pharmaceuticals and Roche/Genentech. Dr. Velazquez-Martin is an ophthalmologist and retina specialist. Previously, Dr. Velazquez-Martin was head of ophthalmology global medical affairs for Bayer in Europe, Canada, and Latin America with a focus on Bayer's ex-U.S. Eylea franchise. His emphasis was on scientific differentiation of Eylea with phase 3 and phase 4 clinical studies design, interpretation and communication.